Safety Study of NY-ESO-1 Protein Vaccine to Treat Cancer Expressing NY-ESO-1

This study has been completed.
Sponsor:
Information provided by:
Ludwig Institute for Cancer Research
ClinicalTrials.gov Identifier:
NCT00106158
First received: March 21, 2005
Last updated: November 4, 2010
Last verified: August 2007
  Purpose

The purpose of this study is to assess the safety of repeated doses of cholesterol-bearing hydrophobized pullulan (CHP) and NY-ESO-1 protein (CHP-NY-ESO-1) and describe the NY-ESO-1 specific-humoral and cellular immune response to immunization with CHP-NY-ESO-1 in patients with cancer expressing NY-ESO-1.


Condition Intervention Phase
Neoplasms
Biological: protein vaccination
Phase 1

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Safety Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Immunization of Patients With Tumors Expressing NY-ESO-1 or LAGE Antigen With Complex of NY-ESO-1 Protein and Cholesterol-bearing Hydrophobized Pullulan (CHP)

Resource links provided by NLM:


Further study details as provided by Ludwig Institute for Cancer Research:

Primary Outcome Measures:
  • NY-ESO-1-specific immune responses

Secondary Outcome Measures:
  • tumor responses

Estimated Enrollment: 9
Study Start Date: June 2004
Study Completion Date: December 2006
Detailed Description:

NY-ESO-1 was isolated by serological analysis of recombinant cDNA expression libraries (SEREX), using tumor mRNA and autologous serum from an esophageal cancer patient. Reverse transcription-polymerase chain reaction (RT-PCR) analysis showed that NY-ESO-1 displayed the typical expression pattern of CT antigens. NY-ESO-1 mRNA was expressed only in testis of normal tissues tested and in various types of cancer, including lung cancer, breast cancer, malignant melanoma and bladder cancer. LAGE-1 was identified by the representational difference analysis and revealed to display 84% amino acid homology with NY-ESO-1. In most cases, expression of LAGE-1 parallels the expression of NY-ESO-1. Since testis is an immune privileged organ where HLA molecules are not expressed, these antigens can be considered tumor-specific.

Because of frequent NY-ESO-1 mRNA expression and high immunogenicity in advanced cancer, NY-ESO-1 is an attractive target molecule for a cancer vaccine. Current therapies against advanced cancer have limited effectiveness. The idea of vaccination with NY-ESO-1 protein in cancer patients with tumors expressing NY-ESO-1 mRNA is based on two findings: 1) the number of CD8+ T cell epitopes identified in NY-ESO-1 molecule are limited to those binding to HLA-A0201, A31, Cw3 and Cw6. These HLA subtypes are carried by a minor Japanese population; 2) CD8+ T cell responses specific to NY-ESO-1 are polyclonal. Protein vaccination may induce immune response more effectively against tumors expressing NY-ESO-1 than peptide immunization.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Histologically proven cancer
  • Confirmed NY-ESO-1 expression
  • No other effective therapy available
  • 4 weeks since conventional therapy before start of the current protocol
  • Performance status < 2 (ECOG scale)
  • Age > 18
  • Able and willing to give written informed consent

Exclusion Criteria:

  • Serious illness
  • Metastatic diseases to central nervous system
  • Concomitant systemic treatment with corticosteroids, anti-histaminic drugs or NSAIDs
  • HIV positive
  • Mental impairment that may compromise the ability to give written informed consent
  • Pregnancy and breastfeeding
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00106158

Locations
Japan
Dept. of Immunology, Okayama University School of Medicine and Dentistry
Okayama, Japan, 700-8558
Sponsors and Collaborators
Ludwig Institute for Cancer Research
Investigators
Principal Investigator: Eiichi Nakayama, MD., PhD Dept. of Immunology, Okayama University Schhol of Medicine and Dentistry
  More Information

Publications:

ClinicalTrials.gov Identifier: NCT00106158     History of Changes
Other Study ID Numbers: LUD2002-005
Study First Received: March 21, 2005
Last Updated: November 4, 2010
Health Authority: Japan: Ministry of Health, Labor and Welfare

Keywords provided by Ludwig Institute for Cancer Research:
cancer/testis antigen
cancer vaccine
recombinant protein

Additional relevant MeSH terms:
Neoplasms

ClinicalTrials.gov processed this record on August 28, 2014